Nasdaq
$0.7331▲ 1.54%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $36.4MShares out 49.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
18- 5d agoAfter-hours26.10.20 05:168-KKey event#●●●
iBio, Inc.
iBio held its 2026 Annual Meeting on October 14, 2026, where stockholders approved an increase in authorized common stock from 275 million to 500 million shares. Additionally, the company approved an amendment to its 2023 Omnibus Incentive Plan, establishing an evergreen provision that automatically increases the number of shares reserved for issuance.…more
$0.7331+1.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 07:344Ownership
iBio, Inc.
Insider Elizabeth Stoner filed a Form 4 with the SEC on October 15, 2026, reporting a change in beneficial ownership of iBio, Inc. securities as of October 14, 2026. This filing serves as the official record of the insider's equity transaction.…more
$0.7331+1.54%vs prev closeView filingShare - 10.15After-hours26.10.16 07:334Ownership
iBio, Inc.
iBio, Inc. insider Alexandra Kropotova filed a Form 4 on October 15, 2026, reporting a change in beneficial ownership of securities as of October 14, 2026. The filing serves as a standard notification of insider activity, though specific transaction volumes or prices were not detailed in the provided document.…more
$0.7331+1.54%vs prev closeView filingShare
17 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Pre-market26.10.13 20:15#●●●#●●●
iBio Highlights Preclinical Data for Obesity Candidate IBIO-610
iBio reported that its IBIO-610 antibody candidate reduced muscle loss when combined with semaglutide in an obese non-human primate study. The company plans to initiate first-in-human trials for the treatment in the first half of 2027.…more
$0.7331+1.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.13Pre-market26.10.13 20:00
●●●●●●●● ●●●●● ●●●●●●
iBio reported that its IBIO-610 antibody helped preserve muscle mass when combined with GLP-1 therapy in non-human primate studies. The company plans to initiate first-in-human trials in the first half of 2027, though these results remain in the early preclinical stage.…more
$0.7331+1.54%vs prev close - 9.1After-hours26.09.02 05:30
●●●●●●●● ●●●●● ●●●●●●
iBio announced its participation in the 21st Annual Wells Fargo Healthcare Conference scheduled for September 8-10, 2026. The company's leadership will engage in a fireside chat and hold one-on-one meetings with investors.…more
$0.7331+1.54%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report